BOCA RATON, Fla., Feb. 16 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) Board of Directors has elected Bruce Downey, Chairman and CEO of Barr Pharmaceuticals, Inc., to serve as its Chairman for 2006-2007. Barr Pharmaceuticals, Inc., headquartered in Woodcliff Lake, New Jersey, develops, manufactures and markets more than 100 generic and proprietary pharmaceutical products.
Mr. Downey has long been active in GPhA and its predecessor organizations and has served several terms on the Executive Committee of GPhA’s Board of Directors.
“We are pleased to welcome Mr. Downey as our new Chairman,” said Kathleen Jaeger, GPhA President and CEO. “He has been an outspoken advocate for the generic industry and a leader on efforts to make generic biopharmaceuticals a reality in the United States. Mr. Downey’s extensive industry knowledge and experience will help us in our efforts to lead America into a healthy future.”
The GPhA Board also elected Heather Bresch, Senior Vice President, Strategic Corporate Development, Mylan Laboratories as its Vice Chairman; Rosendo Ferran, Senior Consultant, New Chemic, Inc., as its Secretary- Treasurer; and William Marth, President and CEO, Teva Pharmaceuticals USA, and Michael Collins, Group President, Mallinckrodt, Inc., to serve as at-large members on its Executive Committee.
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 53% of the total prescriptions dispensed in the United States, but less than 12% of all dollars spent on prescription drugs. For more information about the industry, visit http://www.gphaonline.org.
The Generic Pharmaceutical Association
CONTACT: Andrea Hofelich, +1-703-647-2495, or +1-703-944-3137 (cell), forThe Generic Pharmaceutical Association
Web site: http://www.gphaonline.org/
